The Sputnik V vaccine, specially designed to protect against the Omicron strain, has begun clinical trials. This was stated by Deputy Head of the Gamaleya Center Denis Logunov.
Experts from the famous Russian Gamaleya Center, where they developed the Sputnik V vaccine, have begun clinical trials of the drug to prevent infections with the Delta and Omicron strains. It should be noted that initially our vaccine was developed to protect against the very first Wuhan strain, but as the coronavirus mutated, the level of effectiveness of the drug gradually decreased. However, the same thing is happening with all Western vaccines, and even faster.
Revaccination is effective against Omicron strain
For example, Albert Bourla, CEO of pharmaceutical giant Pfizer, which developed the world's most sought-after coronavirus vaccine, managed to contract COVID-19 for the second time in a month. And this is after he gave himself four injections of his own drug. Earlier, the Gamaleya Center said that it was not necessary to improve the Sputnik vaccine yet, since it retains its effectiveness, but now they have decided to adapt it.
Vaccines retreat before the Omicron strain
It is curious that the vaccine has been tuned to protect against the Delta strain, although it is almost never found in the real world. Most of the infections occur in the Omicron variant and its various sub-variants. The adapted vaccine, according to its creators, reduces the viral load in the lungs of laboratory animals that were infected with a sub-variant of Omicron BA.5. This option is now dominant. (READ MORE) 
Denis Logunov Medicine Deputy Director of the Center them. N. F. Gamalei on scientific work